Genetic Technologies Ltd. engages in the provision of molecular risk assessment tests for cancer. It operates through the following segments: EasyDNA, AffinityDNA, and GeneType/Corporate. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment deals with AffinityDNA branded test sales and expenses. The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987, and is headquartered in Fitzroy, Australia.
Sector:
Commercial Services
Industry:
Miscellaneous Commercial Services
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Genetic Technologies Ltd.?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Genetic Technologies Ltd. market cap is $1,300.00.
What is the 52-week high for Genetic Technologies Ltd.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Genetic Technologies Ltd. 52 week high is $1.00 as of February 25, 2026.
What was Genetic Technologies Ltd. stock price yesterday?
Genetic Technologies Ltd. stock price yesterday was $1.00.
What is the Price-to-Book ratio of Genetic Technologies Ltd.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Genetic Technologies Ltd. P/B ratio is -0.0001.